Lung Biopsy clinical trials

Blood test for monitoring lung cancer after surgery

This study tests whether a simple blood test (liquid biopsy) can help doctors monitor for cancer returning after surgery for early-stage lung cancer. It is for people with non-small cell lung cancer that can be removed with surgery.

Blood tests to monitor advanced lung cancer during care

This study checks whether “liquid biopsies” (blood tests) can help monitor advanced non-small-cell lung cancer. It looks at different patient groups based on timing and tumor features, aiming to make cancer tracking easier and less invasive.

Gene-edited immune cells for advanced melanoma or solid tumors

This Phase 1 study tests a gene-modified immune cell treatment for advanced cancers that don’t have standard curative options. It may help by attacking cancer cells that show a specific marker called IL13Rα2 after patients receive “conditioning” chemotherapy to prepare the immune system.

HOXB7 and lung markers in pulmonary fibrosis

This study looks at a protein called HOXB7 and other markers in lung tissue and blood to better understand pulmonary fibrosis. It may help researchers find new ways to diagnose or treat the disease.

Real-time imaging to diagnose lung cancer faster and safer

This trial tests a new camera tool (confocal laser endomicroscopy) that lets doctors see lung tissue in real-time during a biopsy procedure. The goal is to diagnose non-small cell lung cancer more quickly and safely than standard biopsies alone.

Lung cancer test for EGFR T790M mutation

This trial tests a new blood test that can detect a specific genetic change (EGFR T790M) in advanced lung cancer. It aims to see if the test works well for guiding treatment decisions.

Testing leftover fluid from lymph node biopsies to find lung cancer

This trial is for people who are scheduled for a lung cancer biopsy (EBUS-TBNA) because doctors suspect non-small cell lung cancer (NSCLC) has spread to lymph nodes. It will test leftover fluid from the biopsy to see if it improves cancer detection. If your biopsy is negative but you still need surgery to remove lymph nodes, you can help us learn more about this new test.

Combination therapy for STK11-mutant lung cancer

This trial tests a new drug (GT103) combined with the approved immunotherapy drug pembrolizumab for people with advanced lung cancer that has a specific genetic change (STK11). The goal is to see if adding GT103 helps control the cancer better than pembrolizumab alone.

Finding blood markers that show low oxygen in tumors

This study looks for substances in blood that may reflect how “low-oxygen” a tumor is. If you have head and neck cancer or non-small cell lung cancer, it may help researchers understand tumor oxygen levels and improve future care.

STEMVAC vaccine with pembrolizumab for advanced lung cancer

This trial tests a cancer vaccine called STEMVAC for people with advanced non-small cell lung cancer. The vaccine is given along with ongoing maintenance immunotherapy (pembrolizumab) to see if it can help keep the cancer from growing.

Banking and testing blood samples to study cancer

This study collects blood samples to “test and store” (bank) information that may help doctors understand cancer in the future. You might be able to join if you’re an adult with confirmed cancer or a higher-than-usual risk for cancer.

Check biomarkers during bronchoscopy in breathing and throat pre-cancer

This study looks at “biomarkers” (measurable signals in samples) taken during bronchoscopy or related procedures in people with severe airway pre-cancer or certain lung/throat cancers, and in healthy volunteers. The goal is to better understand what these biomarkers mean and how they might help with diagnosis, staging, or monitoring.

Blood test study to watch for cancer coming back

This study looks at whether blood tests can detect signs that cancer may return after curative-intent treatment. You would have blood drawn around your usual follow-up visits for up to 5 years, and your de-identified health data would be shared with study investigators.

Liquid blood test to predict first immunotherapy response

This trial tests whether a “liquid biopsy” blood test can help predict how well first immunotherapy will work for people with stage IV lung cancer. It may help doctors choose the most effective treatment strategy sooner.

Lung Cancer Biobank Study for Newly Diagnosed Patients

This trial collects blood and tissue samples from people newly diagnosed with lung cancer (NSCLC or CPC) to study the disease over time. It helps researchers understand how different treatments affect the cancer and the body.

Cryogenic catheters tested in donated lung tissue

This study tests a technique using a special cold (cryogenic) catheter to collect samples (biopsy) and destroy abnormal lung tissue (ablation) in lungs outside the body. It’s aimed at improving how pulmonary (lung) lesions could be diagnosed and treated in the future.

Immunotherapy biomarkers for advanced lung cancer

This study looks at blood and tissue biomarkers to predict how well immunotherapy (with or without chemotherapy) works for advanced non-small cell lung cancer. It also helps decide the best second treatment if the first one stops working.

Local anesthesia thoracoscopy for diagnosing unknown fluid around the lung

This study tests a newer, less invasive procedure to diagnose the cause of fluid buildup around the lung. It uses local anesthesia and a small camera to look inside the chest, which may make diagnosis faster and more comfortable.

Personalized vaccine made from your tumor’s new immune targets

This Phase 1 study tests a customized vaccine made from “neo-antigens,” which are new targets found in your tumor. It aims to help your immune system fight certain advanced cancers that have not responded well to prior treatment.

Asthma and nasal polyps study to match immune patterns

This study looks at different “immune inflammation patterns” in people with asthma and/or nasal polyps. It may help researchers better tailor future treatments by figuring out which patterns go with which symptoms.

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors